1 Gamble L J, Matthews Q L. Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther, 2010, 5: 9-26
[2]
2 Fenouillet E, Barbouche R, Jones I M. Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus. AntioxidRedox Signal, 2007, 9: 1009-1034
[3]
3 Devico A, Fouts T, Lewis G K, et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge inmacaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA, 2007, 104: 17477-17482？？
[4]
4 Doms R W, Moore J P. HIV-1 membrane fusion: Targets of opportunity. J Cell Biol, 2000, 151: F9-F14？？
[5]
5 Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science, 1998, 280: 1884-1888？？
[6]
6 Tagliamonte M, Tornesello M L, Buonaguro F M, et al. Conformational HIV-1 envelope on particulate structures: a tool for chemokinecoreceptor binding studies. J Transl Med, 2011, 9(Suppl 1): S1
[7]
7 Buonaguro L, Buonaguro F M, Tornesello M L, et al. High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res, 2001, 49: 35-47
[8]
8 Gheysen D, Jacobs E, D E Foresta F, et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinantbaculovirus-infected insect cells. Cell, 1989, 59: 103-112？？
[9]
9 Yamshchikov G V, Ritter G D, Vey M, et al. Assembly of SIV virus-like particles containing envelope proteins using a baculovirusexpression system. Virology, 1995, 214: 50-58？？
[10]
10 Wagner R, Deml L, Fliessbach H, et al. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology,1994, 200: 162-175？？
[11]
11 Wang B Z, Liu W, Kang S M, et al. Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins intovirus-like particles. J Virol, 2007, 81: 10869-10878？？
[12]
12 Crooks E T, Moore P L, Franti M, et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms ofenvelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology, 2007, 366: 245-262
[13]
13 Yao Q, Bu Z, Vzorov A, et al. Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine, 2003, 21: 638-643？？
[14]
14 Bachmann M F, Lutz M B, Layton G T, et al. Dendritic cells process exogenous viral proteins and virus-like particles for class Ipresentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol, 1996, 26: 2595-2600？？
[15]
15 Deml L, Kratochwil G, Osterrieder N, et al. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins intoPr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology, 1997, 235: 10-25？？
[16]
16 Reimann J, Schirmbeck R. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHCclass I-restricted presentation. Immunol Rev, 1999, 172: 131-152？？
[17]
17 Visciano M L, Diomede L, Tagliamonte M, et al. Generation of HIV-1 Virus-Like Particles expressing different HIV-1 glycoproteins.Vaccine, 2011
[18]
18 Speth C, Bredl S, Hagleitner M, et al. Human immunodeficiency virus type-1 (HIV-1) Pr55gag virus-like particles are potent activators ofhuman monocytes. Virology, 2008, 382: 46-58？？
[19]
19 Deml L, Speth C, Dierich M P, et al. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immuneresponses. Mol Immunol, 2005, 42: 259-277？？
[20]
20 Doan L X, Li M, Chen C, et al. Virus-like particles as HIV-1 vaccines. Rev Med Virol, 2005, 15: 75-88？？
[21]
22 Young K R, Mcburney S P, Karkhanis L U, et al. Virus-like particles: designing an effective AIDS vaccine. Methods, 2006, 40: 98-117？？
24 Seder R A, Hill A V. Vaccines against intracellular infections requiring cellular immunity. Nature, 2000, 406: 793-798？？
[24]
25 Wagner R, Fliessbach H, Wanner G, et al. Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: apossible component of a HIV vaccine. Arch Virol, 1992, 127: 117-137
[25]
26 Sakuragi S, Goto T, Sano K, et al. HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc NatlAcad Sci USA, 2002, 99: 7956-7961？？
[26]
27 Tsunetsugu-yokota Y, Morikawa Y, Isogai M, et al. Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particlesactivate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8(+) T cells by cross-presentation of DCs. J Virol, 2003, 77:10250-10259？？
[27]
21 Lebedev L R, Karpenko L I, Poryvaeva V A, et al. Design of virus-like particles, exposing HIV-1 epitopes. Mol Biol(Mosk), 2000, 34:480-485
